

Applicants: Ron S. Israeli, et al.

Serial No.: 08/403,803

Filed: March 17, 1995

Page 3

Please amend the subject application as follows:

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the specification:

**Listing of Claims:**

1-99. (Canceled)

100. (Currently Amended) A nucleic acid probe which (a) is at least 15 nucleotides in length and (b) hybridizes specifically to a nucleic acid having a sequence set forth in SEQ ID NO:1 ~~No. 1~~, wherein the specific hybridization of the probe to the nucleic acid comprises hybridization conditions which are either i) 65°C in hybridization buffer followed by washing twice in 1xSSPE/1% SDS and twice in 0.1xSSPE/1% SDS at 42°C or ii) 65°C in hybridization buffer and washing twice in 1xSSPE/0.5% SDS at 42°C and twice in 0.1xSSPE/0.5% SDS at 50°C.

101. (Currently Amended) A nucleic acid probe which (a) is at least 15 nucleotides in length and (b) hybridizes specifically to a nucleic acid having a sequence complementary to the DNA sequence set forth in SEQ ID NO:1 ~~No. 1~~, wherein the specific hybridization of the probe to the

nucleic acid comprises hybridization conditions which are either i) 65°C in hybridization buffer followed by washing twice in 1xSSPE/1% SDS and twice in 0.1xSSPE/1% SDS at 42°C or ii) 65°C in hybridization buffer and washing twice in 1xSSPE/0.5% SDS at 42°C and twice in 0.1xSSPE/0.5% SDS at 50°C.

102. (Previously Presented) The nucleic acid probe of claim 100 or 101, wherein the nucleic acid probe is DNA.
103. (Previously Presented) The nucleic acid probe of claim 100 or 101, wherein the nucleic acid probe is RNA.
104. (Previously Presented) The nucleic acid probe of claim 100 or 101, wherein the nucleic acid probe is labeled with a detectable marker.
105. (Previously Presented) The nucleic acid probe of claim 104, wherein the detectable marker is a radioactive label or fluorescent label.
- 106-112. (Canceled)
113. (Currently Amended) An isolated nucleic acid which encodes an antigenic prostate specific membrane antigen polypeptide

comprising consecutive amino acids, the sequence of which amino acids corresponds to the sequence of all or less than all of an outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus, provided that the prostate specific membrane antigen polypeptide so encoded is characterized by antigenicity, wherein the isolated nucleic acid is further characterized by being able to hybridize specifically to the nucleic acid sequence set forth in SEQ ID NO:1 or a nucleic acid sequence complementary thereto, wherein the specific hybridization of the isolated nucleic acid to the nucleic acid sequence or the nucleic acid sequence complementary thereto comprises hybridization conditions of either i) 65°C in hybridization buffer followed by washing twice in 1xSSPE/1% SDS and twice in 0.1xSSPE/1% SDS at 42°C or ii) 65°C in hybridization buffer and washing twice in 1xSSPE/0.5% SDS at 42°C and twice in 0.1xSSPE/0.5% SDS at 50°C.

114. (Currently Amended) An isolated nucleic acid which encodes an antigenic prostate specific membrane antigen polypeptide:

Applicants: Ron S. Israeli, et al.

Serial No.: 08/403,803

Filed: March 17, 1995

Page 6

(A) consisting essentially of consecutive amino acids, the sequence of which corresponds to the sequence of all or less than all of an outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus, and

(B) ~~which encoded prostate specific membrane antigen polypeptide is~~ characterized by antigenicity and ~~comprises~~ the presence within it of each of the following sequences:

(a) Asp-Glu-Leu-Lys-Ala-Glu  
(SEQ ID NO: 35);

(b) Asn-Glu-Asp-Gly-Asn-Glu  
(SEQ ID NO: 36); and

(c) Lys-Ser-Pro-Asp-Glu-Gly  
(SEQ ID NO: 37).

115. (Currently Amended) An isolated nucleic acid which encodes an antigenic prostate specific membrane antigen polypeptide:

(A) consisting essentially of a fragment of prostate specific membrane antigen, which fragment has a sequence which is the same as the

sequence of all or less than all of an antigenic outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is included within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus, and

(B) which encoded prostate specific membrane antigen fragment is characterized by antigenicity and comprises the presence within it of each of the following sequences:

- (a) Asp-Glu-Leu-Lys-Ala-Glu  
(SEQ ID NO: 35);
- (b) Asn-Glu-Asp-Gly-Asn-Glu  
(SEQ ID NO: 36); and
- (c) Lys-Ser-Pro-Asp-Glu-Gly  
(SEQ ID NO: 37).

116. (Previously Presented) An isolated nucleic acid having within its structure at least 15 consecutive nucleotides having a sequence which is present in the sequence set forth in SEQ ID NO:1 and encoding a fragment of prostate specific membrane antigen.

117. (Previously Presented) An isolated nucleic acid having within its structure at least 15 consecutive nucleotides having a

sequence which is complementary to a sequence present in the sequence set forth in SEQ ID NO:1.

118. (Previously Presented) The isolated nucleic acid of claim 116, wherein the isolated nucleic acid encodes an antigenic domain of prostate specific membrane antigen.

119. (Previously Presented) The isolated nucleic acid of claim 116, wherein the fragment has a sequence which is the same as a sequence of all or less than all of an outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus.

120. (Currently Amended) An isolated nucleic acid which encodes an antigenic fragment of prostate specific membrane antigen, which fragment is characterized by antigenicity and has a sequence which is the same as a sequence of all or less than all of an outside region of prostate specific membrane antigen, the amino acid sequence of which outside region is set forth within SEQ ID NO:2 beginning with amino acid number 45 at the amino terminus, and the antigenic fragment comprises

consecutive amino acids having a sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37 and SEQ ID NO:38, provided that if the antigenic fragment comprises consecutive amino acids having the sequence set forth in SEQ ID NO:35, the antigenic fragment further comprises at least one additional amino acid present in SEQ ID NO:2, provided that the sequence of the antigenic fragment is included within SEQ ID NO:2.

121. (Currently Amended) An isolated nucleic acid which is at least 15 nucleotides in length and specifically hybridizes to the nucleic acid of any one of claims 113-120, wherein the isolated nucleic acid is further characterized by being able to hybridize specifically to the nucleic acid sequence set forth in SEQ ID NO:1 or a nucleic acid sequence complementary thereto, wherein the specific hybridization of the isolated nucleic acid to the nucleic acid sequence or the nucleic acid sequence complementary thereto comprises hybridization conditions of either i) 65°C in hybridization buffer followed by washing twice in 1xSSPE/1% SDS and twice in 0.1xSSPE/1% SDS at 42°C or ii) 65°C in hybridization buffer and washing

twice in 1xSSPE/0.5% SDS at 42°C and twice  
in 0.1xSSPE/0.5% SDS at 50°C.

122. (Previously Presented) A vector which comprises the isolated nucleic acid of any one of claims 113-120.
123. (Previously Presented) The vector of claim 122, wherein the vector is a plasmid.
124. (Previously Presented) A host vector system for the production of a polypeptide which comprises the vector of claim 122 and a suitable host cell.
125. (Previously Presented) The host vector system of claim 124, wherein the suitable host cell is a bacterial cell, insect cell, or mammalian cell.
126. (Previously Presented) A method of producing a polypeptide which comprises using the host vector system of claim 125 under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.